trial
type: MedicalStudy
name: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
description: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
status: RECRUITING
study design: INTERVENTIONAL
phase: PHASE3
start date: 2022-08-31
end date: 2026-10
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT05281471
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Genelux Corporation
study subject: Platinum-resistant Ovarian Cancer
study subject: Platinum-refractory Ovarian Cancer
study subject: Fallopian Tube Cancer
study subject: Primary Peritoneal Cancer
study subject: High-grade Serous Ovarian Cancer
study subject: Endometrioid Ovarian Cancer
study subject: Ovarian Clear Cell Carcinoma
keywords: PHASE3
keywords: INTERVENTIONAL
keywords: RECRUITING
keywords: Platinum-resistant Ovarian Cancer
keywords: Platinum-refractory Ovarian Cancer
keywords: Fallopian Tube Cancer
keywords: Primary Peritoneal Cancer
keywords: High-grade Serous Ovarian Cancer

AI Analytics
type: Organization